Gain Therapeutics, Inc.

Listed Company

GANXCIK 0001819411NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-20.16M

Total Assets

$22.82M

Equity

$18.56M

Shares Out

42.65M

Op. Cash Flow

$-18.47M

GANX$1.71+5.57% · past yearDBEQ Basic

Daily closing prices

Business

Gain Therapeutics is a biotechnology company developing novel small-molecule therapeutics targeting protein misfolding and degradation across central nervous system disorders, lysosomal storage diseases, metabolic disorders, and oncology. The company's lead product candidate, GT-02287, is in Phase 1b clinical trials for Parkinson's disease and potential use in other neurodegenerative and lysosomal storage conditions. The company employs a proprietary computational drug discovery platform called Magellan™ to identify allosteric binding sites on disease-implicated proteins and design structurally targeted allosteric regulators (STARs) that stabilize, destabilize, or otherwise modulate protein function.

Summary from 10-K filed 2026-03-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	−10	−11	−12	−8	−7
General and administrative	−8	−10	−11	−10	−7
Total operating expenses	−19	−20	−22	−18	−14
Loss from operations	−19	−20	−22	−18	−14
Interest income, net	244,394	357,096	494,234	—	—
Foreign exchange (loss) gain, net	−833,673	119,120	−429,346	−96,074	−72,920
Loss before income tax	−19	−20	−22	−17	−14
Income tax	−861,118	−536,815	−79,275	−92,976	−4,008
Net loss	−20	−20	−22	−18	−14
Net loss per share attributable to common stockholders - basic	−0.61	−0.89	−1.71	−1.48	−1.37
Net loss per share attributable to common stockholders - diluted	−0.61	−0.89	−1.71	−1.48	−1.37
Weighted average common stock - basic	33	23	13	12	10
Weighted average common stock - diluted	33	23	13	12	10

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	21	10	12	7	37
Tax credits	179,701	271,079	242,577	103,877	113,586
Prepaid expenses and other current assets	1	945,536	741,638	848,854	727,785
Total current assets	22	12	18	21	38
Property and equipment, net	74,916	103,619	125,962	144,379	105,986
Internal-use software, net	102,837	134,268	193,375	213,967	202,609
Operating lease right-of-use assets	334,090	219,715	459,215	659,933	901,042
Restricted cash	36,296	31,695	34,021	30,818	31,279
Long-term deposits and other noncurrent assets	33,698	32,109	17,890	17,506	22,111
Total noncurrent assets	581,837	521,406	830,463	3	1
Total assets	23	12	19	24	39
Accounts payable	800,000	900,000	1	2	560,479
Operating lease liabilities - current	119,876	160,913	229,693	229,080	219,137
Other current liabilities	2	2	2	2	1
Deferred grant income - current	—	252,211	1	55,180	266,504
Loans - current	100,869	110,177	118,797	108,135	103,826
Total current liabilities	3	4	5	4	3
Defined benefit pension plan	390,509	443,623	307,454	157,580	329,458
Operating lease liabilities - noncurrent	211,238	53,598	229,855	441,784	695,053
Deferred grant income - noncurrent	—	47,441	94,786	—	—
Loans - noncurrent	300,084	328,327	449,053	495,258	590,468
Total noncurrent liabilities	901,831	872,989	1	1	2
Total liabilities	4	5	6	5	4
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of December 31, 2025 and 2024	—	—	—	—	—
Common stock, $0.0001 par value: 100,000,000 shares authorized; 42,073,807 and 27,132,588 shares issued and outstanding as of December 31, 2025 and 2024, respectively	4,209	2,713	1,621	1,189	1,189
Additional paid-in capital	119	89	73	57	56
Accumulated other comprehensive income (loss)	776,869	−247,549	247,241	35,627	−90,645
Accumulated deficit	−81	−61	−39	−21	−7
Loss of the period	−20	−20	−22	−18	−14
Total stockholders' equity	19	7	13	19	35
Total liabilities and stockholders' equity	23	12	19	24	39

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−20	−20	−22	−18	−14
Depreciation and amortization	94,046	84,071	83,579	64,168	15,484
Stock-based compensation expense	2	2	3	2	839,371
Other non-cash items	804,938	143,523	−383,188	−206,861	—
Prepaid expenses and other current assets	−82,119	−356,650	54,378	−114,005	−534,502
Long term deposit and other noncurrent assets	2,852	−21,000	−10,057	−2,901	33,979
Accounts payable and other current liabilities	−468,606	274,889	−693,698	—	—
Defined benefit pension plan	−130,568	−122,915	6,313	—	—
Deferred grant income	−328,071	−854,713	1	−208,343	34,701
Total changes in operating assets and liabilities	−1	−1	442,230	2	−329,784
Cash used in operating activities	−18	−19	−19	−15	−12
Purchase of property and equipment and internal-use software	—	−22,493	−15,358	−118,953	−94,212
Maturities of marketable securities	—	5	12	—	—
Cash provided by investing activities	—	5	10	−15	−94,212
Net proceeds from issuance of shares in 2024 ATM Program (Note 14)	18	3	4	—	—
Net proceeds from issuance of shares in public offering (Note 14)	7	10	9	—	—
Net proceeds from the exercise of warrants (Note 14)	3	113,800	—	—	—
Net proceeds from the exercise of stock options (Note 15)	250,260	57,711	—	—	12,216
Payments of offering costs (Note 14)	−395,478	−280,867	—	—	−853,488
Payments of current portion of long-term debt (Note 12)	−96,501	−90,879	−89,067	−78,774	−21,951
Cash provided by financing activities	28	13	13	−78,774	42
Effect of exchange rate changes	474,032	−527,168	488,404	−23,797	100,778
Net increase (decrease) in cash, cash equivalents and restricted cash	10	−1	4	−30	29
Income taxes paid	47,549	86,309	134,962	2,740	4,469

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Gain Therapeutics, Inc.'s CIK number?

Gain Therapeutics, Inc.'s SEC CIK number is 0001819411 (1819411). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Gain Therapeutics, Inc.'s SEC filings?

All of Gain Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Gain Therapeutics, Inc. last report earnings?

Gain Therapeutics, Inc. (GANX) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-058636). This is Gain Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Gain Therapeutics, Inc.'s most recent earnings 8-K?

Gain Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001104659-26-058636. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Gain Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →